Key insights
- Gilead extended its tender offer for Arcellx to April 27, 2026, after receiving regulatory approvals. The acquisition, aimed at expanding Gilead's oncology portfolio, is progressing with customary closing conditions. Gilead's strong financial health supports the deal. The market impact is slightly positive, reflecting reduced uncertainty about the deal's completion.
FOSTER CITY, Calif. - Gilead Sciences Inc. (NASDAQ:GILD) has extended the expiration of its tender offer to acquire Arcellx to 5:00 p.m. Eastern Time on April 27, 2026, the company said in a press release statement Thursday. The $172 billion biotech giant, which InvestingPro identifies as a prominent player in the Biotechnology industry, continues to pursue the strategic acquisition as it expands its oncology portfolio.
The company received all required regulatory approvals for the acquisition. The Australian Competition and Consumer Commission published its decision on April 13, 2026, allowing the transaction to proceed subject to a 14-calendar day waiting period that expires at 10:00 a.m. Eastern Time on April 27, 2026. The review period for Austrian competition authorities has also expired.
The tender offer was previously scheduled to expire on April 24, 2026. The offer remains subject to customary closing conditions, including the tender of shares that, together with shares already owned by Gilead, equal at least a majority of outstanding Arcellx shares. Gilead’s financial position remains solid with a "GREAT" financial health score and strong cash flows to support the acquisition, according to InvestingPro data. The company reports earnings in six days, with analysts forecasting continued profitability. For deeper insights into Gilead’s acquisition strategy and financial outlook, investors can access the comprehensive Pro Research Report, available for GILD and 1,400+ other US equities.
The purchase price remains at $115.00 per share in cash, plus one contractual contingent value right. The CVR represents the right to receive one contingent payment of $5.00 per CVR in cash, payable on March 31, 2030, subject to cumulative worldwide sales of Arcellx’s anitocabtagene autoleucel product exceeding $6.0 billion on or prior to December 31, 2029.
As of 4:00 p.m. Eastern Time on Wednesday, approximately 10,271,823 shares had been validly tendered and not withdrawn, representing approximately 17.5% of outstanding shares, according to Computershare Trust Company, N.A., the depositary and paying agent for the tender offer.
Shareholders who have previously tendered their shares do not need to re-tender or take any other action in response to the extension.
In other recent news, Gilead Sciences Inc. has announced a collaboration with the U.S. State Department, PEPFAR, and The Global Fund to expand access to its HIV prevention drug, lenacapavir, to an additional 1 million people. This initiative aims to reach a total of 3 million individuals in high-incidence, resource-limited countries by 2028. Meanwhile, Truist Securities has raised its price target for Gilead Sciences to $155, maintaining a Buy rating, based on anticipated merger and acquisition activity. The firm forecasts Gilead’s first-quarter 2026 revenue to be approximately $6.94 billion, slightly above the consensus of $6.91 billion, with non-GAAP earnings per share expected at $1.84.
In a separate development, Gilead has expanded its collaboration with Tempus AI Inc., focusing on advancing its oncology pipeline. This agreement grants Gilead access to Tempus’ AI-driven Lens platform, which includes a vast array of de-identified multimodal data and analytical services. Additionally, RBC Capital has reiterated a Sector Perform rating for Gilead Sciences, with a price target of $123, as they continue to assess trends related to the Yeztugo drug. These developments highlight Gilead’s strategic initiatives in both HIV prevention and oncology research.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.